Literature DB >> 31272957

Long-term outcomes of ocular adnexal lesions in IgG4-related ophthalmic disease.

Toshinobu Kubota1, Masao Katayama2, Reiko Nishimura3, Suzuko Moritani4.   

Abstract

AIMS: To determine the long-term outcomes of ocular adnexal lesions in immunoglobulin G4-related ophthalmic disease (IgG4-ROD).
METHODS: This retrospective, non-randomised exploratory study included 82 patients with ocular adnexal lesions. We evaluated the long-term outcomes in 71 patients during the median follow-up period of 30 months, who underwent either watchful waiting (n=20; range 12-90 months) or systemic corticosteroid treatment, delivered according to consensus guidelines (n=51; range 9- 115 months). We also analysed factors that might contribute to recalcitrance to treatment.
RESULTS: Of 82 patients, 40 (49%) were male, and the median patient age was 60 years old. Twenty-one (26%) patients with extraocular muscle (EOM) and/or trigeminal nerve branch (CN V) enlargements had a significantly high frequency of multiple ocular adnexal lesions (p<0.0001, Fisher's exact test). In addition, two patients developed EOM and/or CN V enlargements de novo over time. Twenty patients with solitary lacrimal gland enlargements preferred watchful waiting, due to mild symptoms. Of these, 18 (90%) lesions remained dormant throughout a median follow-up of 27 months. Among 51 patients treated with corticosteroids, 31 (61%) experienced relapses after treatment and required systemic low-dose maintenance treatment. A multivariate analysis indicated that EOM and/or CN V enlargements comprised a risk factor for relapse (HR 2.7; 95% CI 1.1 to 6.7).
CONCLUSIONS: This exploratory study showed that different types of ocular adnexal lesions in IgG4-ROD displayed distinct proliferative activities. Our results suggested that EOM and/or CN V enlargements might be secondary lesions that confer refractoriness to systemic corticosteroid treatment recommended by consensus guidelines. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  lacrimal gland; orbit

Year:  2019        PMID: 31272957     DOI: 10.1136/bjophthalmol-2018-313730

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

1.  Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation.

Authors:  Toshinobu Kubota; Akari Iwakoshi
Journal:  BMJ Open Ophthalmol       Date:  2022-06

2.  Natural developing process of immunoglobulin G4-related sialadenitis after submandibular gland excision: a retrospective cohort study.

Authors:  Ke-Fu Zhang; Xia Hong; Wei Li; Yan Gao; Yan Chen; Yan-Yan Zhang; Jia-Zeng Su; Xin Peng; Guang-Yan Yu
Journal:  Clin Rheumatol       Date:  2021-07-18       Impact factor: 2.980

3.  Follow-up with serum IgG4-monitoring in 8 patients with IgG4-related disease diagnosed by a lacrimal gland mass.

Authors:  Toshihiko Matsuo; Takehiro Tanaka; Yasuharu Sato; Hitomi Kataoka; Mayu Uka; Daisuke Ennishi; Tomofumi Yano
Journal:  J Clin Exp Hematop       Date:  2021

4.  Morphologic Cross-Sectional Imaging Features of IgG4-Related Orbitopathy in Comparison to Ocular Adnexal Lymphoma.

Authors:  Annemarie Klingenstein; Aylin Garip-Kuebler; Siegfried Priglinger; Christoph Hintschich; Ullrich G Mueller-Lisse
Journal:  Clin Ophthalmol       Date:  2021-03-12

5.  Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients.

Authors:  Linyang Gan; Xuan Luo; Yunyun Fei; Linyi Peng; Jiaxin Zhou; Jieqiong Li; Hui Lu; Zheng Liu; Panpan Zhang; Xiaowei Liu; Wen Zhang
Journal:  BMC Ophthalmol       Date:  2021-12-27       Impact factor: 2.209

6.  Long-Term Outcomes of IgG4-Related Ophthalmic Disease in a Chinese IgG4-Related Disease Cohort.

Authors:  Linyang Gan; Xuan Luo; Yunyun Fei; Linyi Peng; Jiaxin Zhou; Jieqiong Li; Hui Lu; Zheng Liu; Panpan Zhang; Xiaowei Liu; Wen Zhang
Journal:  Front Med (Lausanne)       Date:  2021-12-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.